Possible role of nondopaminergic drugs on levodopa-induced dyskinesias in Parkinson’s disease

References

• Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov. Disord 13,871–876 (1998).
   PubMed Web of Science ®Google Scholar
• Grandas F, López-Ariztegui N. Fisiopatologia de las discinesias inducidas por L-dopa. In: Enfermedad de Parkinson. Luquin MR, Jimenez-Jimenez FJ (Eds). Rev Neurol. 25 (Suppl. 2), S151-S156 (1997).
   Google Scholar
• Grandas FJ. Complicaciones motoras asociadas con el tratamiento creinico de la enfermedad de Parkinson. In: Tratado sobre la enfermedad de Parkinson. Obeso JA, Tolosa E, Grandas F (Eds). Luzen 5 SA de Ediciones, Madrid, Spain, 267–280 (1997).
   Google Scholar
• Jimenez-Jimenez FJ, Molina JA, Orti-Pareja M. Mecanismos farmacológicos del tratamiento de las discinesias en la enfermedad de Parkinson. Rev Neurol. 28, 889–898 (1999).
   Google Scholar
• Herrero MT, Levy R, Ruberg M, et al. Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum. Neurology47,219–224 (1996).
   Google Scholar
• Luquin MR, Jimenez-Jimenez FJ. Anatomia ftmcional de los ganglios basales. In: Tratado de los imstornos del Movimiento. Jimenez-Jimenez FJ, Luquin MR, Molina JA (Eds), IM&C, Madrid, Spain, 19–41 (1998).
   Google Scholar
• Calon F, Goulet M, Blanchet PJ et al. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex. Brain Res. 680, 43–52 (1995).
   Google Scholar
• Robertson RG, Clarke CA, Boyce S, Sambrook MA, Crossman AR. The role of striopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced Parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography. Brain Res. 531: 95–104 (1990).
   Google Scholar
• Mitchell U, Boyce S, Sambrook MA, Grossman AR. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain 115,809–824 (1992).
   Google Scholar
• Blanchet PJ, Boucher R, Bedard PJ. Excitotoxic lateral pallidotomy does not relieve L-dopa-induced dyskinesia in MPTP parkinsonian monkeys. Brain Res. 650, 32–39 (1994).
   Google Scholar
• Trugman JM, Hubbard CA, Bennet JP, Jr. Dose-related effects of continuous levodopa infusion in rats with unilateral lesions of the substantia nigra. Brain Res. 725, 177–183 (1996).
   Google Scholar
• Gershanik OS, Luquin MR, Scipioni O, Obeso JA. Isoniazid therapy in Parkinson's disease. Mov. Disord. 3, 133–139 (1988).
   Google Scholar
• Price PA, Parkes JD, Marsden CD. Sodium valproate in the treatment of levodopa-induced dyskinesias. j Neurol. Neurosurg. Psychiatry 41, 702–706 (1978).
   Google Scholar
• Morselli PL, Fournier V, Bossi L, Musch B. Clinical activity of GABA agonists in neuroleptic- and L-dopa-induced dyskinesia. Psychopharmacology 2 (Suppl.), 128–136 (1985).
   Google Scholar
• Ziegler M, Fournier V, Bathien N, Morselli PL, Rondot P Therapeutic response to progabide in neuroleptic- and L-dopa-induced dyskinesias. Clin. Neuropharmacol. 10, 238–246 (1987).
   Google Scholar
• Turjanski N, Lees AJ. Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias. j Neurol. Neurosurg. Psychiatry 55, 413 (1992).
   Google Scholar
• Voorn P, Roest G, Groenewegen HJ. Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions. Brain Res. 412, 391–398 (1987).
   Google Scholar
• Jenner P The rationale for the use of dopamine agonists in Parkinson's disease. Neurology45\(Suppl. 3), S6—S12 (1995).
   Google Scholar
• Cenci MA, Lee CS, Bjorklund A. L- DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. j Neurosci. 10, 2694–2706 (1998).
   Google Scholar
• Nisbet AR Foster OJF, Kingsbury A, Lees AJ. Regional striatal neuropeptide expression in Parkinson's disease: a quantitative in situ hybridisation study. 11th International Symposium on Parkinson's disease, Roma, 1994. N Trends Clin. Neuropharmacol. 60–61 (1984).
   Google Scholar
• Morissette M, Grondin R, Goulet M, Bedard PJ, Di Paolo T. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists. Neurochem. 72, 682–692 (1999).
   Google Scholar
• Piccini P, Weeks RA, Brooks DJ. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann. Neurol. 42, 720–726 (1997).
   Google Scholar
• Henry B, Brotchie JM. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs Aging9, 149–158 (1996).
   PubMedGoogle Scholar
• Henry B, Fox SH, Grossman AR, Brotchie J. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp. Neurol. 171, 139–146 (2001).
   PubMed Web of Science ®Google Scholar
• Carey RJ. Naloxone reverses L-dopa induced overstimulation effects in a Parkinson's disease animal model analogue. Life Sci. 48, 1303–1308 (1991).
   PubMedGoogle Scholar
• Sandyk R, Snider SR. Naloxone treatment of L-dopa-induced dyskinesias in Parkinson's disease. Am. j Psychiatry143, 118 (1986).
   PubMed Web of Science ®Google Scholar
• Rascol O, Fabre N, Blin O et al. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov. Disord. 9, 437–440 (1994).
   PubMed Web of Science ®Google Scholar
• Manson AJ, Katzenschlager R, Hobart J, Lees AJ. High dose naltrexone for dyskinesias induced by levodopa. j Neurol. Neurosurg. Psychiatry 70, 554–556 (2001).
   Google Scholar
• Miller R, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol. Psychiatry 34, 713–738 (1993).
   PubMed Web of Science ®Google Scholar
• GOrnez-Mancilla B, Bedard PJ. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin. Neuropharmacol. 16, 418–427 (1993).
   Google Scholar
• Hauser RA, Olanow CW. Orobuccal dyskinesia associated with trihexyphenydil therapy in a patient with Parkinson's disease. Mov. Disord. 8, 512–514 (1993).
   Google Scholar
• Linazasoro G. Anticholinergics and dyskinesia. Mov. Disord 9, 689 (1994).
   Google Scholar
• Tarsy D, Leopold N, Sax D. Physostigmine in choreiform movement disorders. Neurology24, 28–34 (1974).
   Google Scholar
• Klawans HL, Topel JL, Bergen D. Deanol in the treatment of levodopa-induced dyskinesias. Neurology 25, 290–293 (1975).
   Google Scholar
• Osvaldo NR. Deanol in L-dopa and tardive dyskinesias: a review. CUIT: Ther. Res. Clin. Exp. 18, 872–875 (1975).
   Google Scholar
• Miller E. Deanol in the treatment of levodopa-induced dyskinesias. Neurology 24, 116–119 (1974).
   Google Scholar
• Lindeboom SF, Lakke JP Deanol and physostigmine in the treatment of L-dopa-induced dyskinesias. Acta Neurol. Scand 58, 134–138 (1978).
   Google Scholar
• Friedman A. W sprawie patomechanizmu dyskinez zwiazanych z leczeniem choroby parkinsona preparatami L-dopa. Doniesienie wstepne. Neurol. Neurochir Pol. 15, 407–409 (1981).
   Google Scholar
• Fox SH, Brotchie JM. 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Mov. Disord 15, 1064–1069 (2000).
   Google Scholar
• Bibbiani F, Oh JD, Chase TN. Serotonine 5- HT 1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57, 1829–1834 (2001).
   Google Scholar
• Kannari K, Kurahashi K, Tomiyama M et al. Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease. No To Shinkei 54, 133–137 (2002).
   PubMedGoogle Scholar
• Papavasilliou PS, Cotzias GC, McDowell FH, Rosal VL, Sheehan PJ. Cyproheptadine in levodopa-induced dyskinesia in parkinsonism. Clin. Pharmacol. Ther. 23, 195–198 (1978).
   Google Scholar
• El-Awar M, Freedman M, Seeman P, Goldenberg L, Little J, Solomon P Response of tardive and L-dopa-induced dyskinesias to antidepressants. Can. Neurol. Sci. 14, 629–631 (1987).
   Google Scholar
• Durif F, Vidailhet M, Bonnet AM, Blin J, Agid Y. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 45, 1855–1858 (1995).
   Google Scholar
• Papa SM, Chase TM. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann. Neurol. 39, 574–578 (1996).
   PubMed Web of Science ®Google Scholar
• Blanchet PJ, Papa SM, Metman LV, Mouradian MM, Chase TN. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci Biobehav. Rev 21, 447–453 (1997).
   Google Scholar
• Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. j Pharmacol. Rip The,: 290, 1034–140 (1999).
   Google Scholar
• Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54, 1589–1595 (2000).
   Google Scholar
• Verhagen-Metman L, Blanchet PJ, van den Munckhof P, Del Dotto P, Ante R, Chase TN. A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord 13, 414–417 (1998).
   Google Scholar
• Verhagen-Metman L, Del Dotto P, Natte R, van den Munckhof P, Chase TN. Dextrometorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology51, 203–206 (1998).
   Google Scholar
• Verhagen-Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50, 1323–1326 (1998).
   Google Scholar
• Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch. Neurol 56, 1383–1386 (1999).
   Google Scholar
• Snow BJ, Macdonald L, Mcauley D, Wallis W The effect of levodopa-induce dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin. Neuropharmacol 23, 82–85 (2000).
   PubMed Web of Science ®Google Scholar
• Cersosimok MG, Scorticati MC, Micheli FE. Amantadine para el tratamiento de las disquinesias inducidas por levodopa en la enfermedad de Parkinson. Medicina fl3 Aires) 60, 321–325 (2000).
   Google Scholar
• Del Dotto P, Pavese N, Gambaccini G et al. Intravenous amantadine improves levodopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov. Disord 16, 515–520 (2001).
   PubMed Web of Science ®Google Scholar
• Merims D, Ziv I, Djaldetti R, Melamed E. Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease. Lancet353, 1764–1765 (1999).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Evaluation of dyskinesias in a pilot, randomised, placebo-controlled trial of remacemide in advanced Parkinson's disease. Arch. Neurol 58, 1660–1668 (2001).
   PubMed Web of Science ®Google Scholar
• Manson AJ, Iakovidou E, Lee AJ. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease. Mov. Disord 15, 336–337 (2000).
   Google Scholar
• Grondin R, Bedard PJ, Hadj-Tahar A, Gregoire L, Mori A, Kase H. Antiparkinson effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 52, 1673–1677 (1999).
   Google Scholar
• Kulisevsky J, Barbanoj M, Gironell A, Antonijoan R, Casas M, Pascual-Sedano B. A double-blind crossover, placebo-controlled study of the adenosine A2A antagonists theophylline in Parkinson's disease. Clin. Neuropharmacol. 25, 25–21 (2002).
   Google Scholar
• Boyce S, Rupniak NM, Steventon M, Iversen SD. CCK-85 inhibits L-dopa-induced dyskinesias in parkinsonian squirrel monkeys. Neurology 40, 717–718 (1990).
   Google Scholar
• Gomez-Mancilla B, Bedard PJ. Effect of estrogen and progesterone on L-dopa induced dyskinesia in MPTP-treated monkeys. Neurosci. Lett. 135, 129–132 (1992). Affiliations
   Google Scholar